These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 8236823)
41. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis. Riethdorf L; Begemann C; Riethdorf S; Milde-Langosch K; Löning T Virchows Arch; 1996 Apr; 428(1):47-51. PubMed ID: 8646368 [TBL] [Abstract][Full Text] [Related]
42. [Characteristic and clinical significance of DNA methyltransferase 3B overexpression in endometrial carcinoma]. Dong Y; Zhou M; Ba XJ; Si JW; Li WT; Wang Y; Li D; Li T Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):788-794. PubMed ID: 27752157 [TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Shiozawa T; Xin L; Nikaido T; Fujii S Int J Gynecol Pathol; 1997 Oct; 16(4):348-53. PubMed ID: 9421074 [TBL] [Abstract][Full Text] [Related]
44. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis? Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281 [TBL] [Abstract][Full Text] [Related]
45. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803 [TBL] [Abstract][Full Text] [Related]
46. [Study of estrogen and progesterone receptors in endometrial carcinoma]. Chen Y; Peng Z Hua Xi Yi Ke Da Xue Xue Bao; 2000 Mar; 31(1):98-100. PubMed ID: 12501628 [TBL] [Abstract][Full Text] [Related]
47. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Lax SF; Pizer ES; Ronnett BM; Kurman RJ Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308 [TBL] [Abstract][Full Text] [Related]
48. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps. Giordano G; Gnetti L; Merisio C; Melpignano M Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204 [TBL] [Abstract][Full Text] [Related]
49. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788 [TBL] [Abstract][Full Text] [Related]
50. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma. Li M; Zhao L; Shen D; Li X; Wang J; Wei L Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589 [TBL] [Abstract][Full Text] [Related]
51. Expression of gonadal steroid receptors in the ovaries of post-menopausal women with malignant or benign endometrial pathology: a pilot study. Panoulis K; Christantoni E; Pliatsika P; Anagnostis P; Goulis DG; Kondi-Pafiti A; Armeni E; Augoulea A; Triantafyllou N; Creatsa M; Lambrinoudaki I Gynecol Endocrinol; 2015; 31(8):613-7. PubMed ID: 26036714 [TBL] [Abstract][Full Text] [Related]
52. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer. Singer CF; Kronsteiner N; Marton E; Walter I; Kubista M; Czerwenka K; Schreiber M; Tschugguel W; Wieser F; Kubista E Gynecol Oncol; 2002 Jun; 85(3):423-30. PubMed ID: 12051868 [TBL] [Abstract][Full Text] [Related]
53. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303 [TBL] [Abstract][Full Text] [Related]
54. Androgen Receptor Expression in Endometrial Carcinoma. Zadeh SL; Duska LR; Mills AM Int J Gynecol Pathol; 2018 Mar; 37(2):167-173. PubMed ID: 28582344 [TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020 [TBL] [Abstract][Full Text] [Related]
56. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107 [TBL] [Abstract][Full Text] [Related]
58. Sex steroid hormones and receptors in relation to S-phase fraction and ploidy level in endometrial carcinoma. Boman K; Mäentausta O; Bäckström T; Strang P; Stendahl U Anticancer Res; 1995; 15(3):999-1002. PubMed ID: 7645992 [TBL] [Abstract][Full Text] [Related]
59. Steroid receptor expression in endometria from women treated with tamoxifen. Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688 [TBL] [Abstract][Full Text] [Related]
60. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. Sivridis E; Giatromanolaki A J Clin Pathol; 2004 Aug; 57(8):840-4. PubMed ID: 15280405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]